Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.094 AUD | +2.17% | -4.08% | +327.27% |
04-30 | Nyrada's NYR-BI03 Being Studied For Potential in Traumatic Brain Injury | MT |
04-18 | Transcript : Nyrada Inc., Q3 2024 Earnings Call, Apr 18, 2024 |
Business Summary
Sales per Business
AUD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Drug Development
100.0
%
| 1 | 100.0 % | 1 | 100.0 % | +36.40% |
Sales per region
AUD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 1 | 100.0 % | 1 | 100.0 % | +36.40% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
James Bonnar
CEO | Chief Executive Officer | - | 31/01/18 |
Founder | - | 28/08/17 | |
Chief Tech/Sci/R&D Officer | - | - | |
Benjamin Evison
CTO | Chief Tech/Sci/R&D Officer | - | 28/08/17 |
Investor Relations Contact | - | 31/05/23 | |
David Franks
SEC | Corporate Secretary | 53 | - |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Founder | - | 28/08/17 | |
Ruediger Weseloh
BRD | Director/Board Member | - | 31/05/19 |
Marcus Frampton
BRD | Director/Board Member | 44 | 31/05/19 |
John Moore
CHM | Chairman | 59 | 15/07/19 |
Christopher Cox
BRD | Director/Board Member | 59 | 31/10/19 |
Ian Dixon
BRD | Director/Board Member | - | 31/08/20 |
Gisela Mautner
BRD | Director/Board Member | - | 31/07/22 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 156,008,700 | 46,854,283 ( 30.03 %) | 0 | 30.03 % |
Company contact information
Sector
1st Jan change | Capi. | |
---|---|---|
+327.27% | 10.72M | |
+33.25% | 699B | |
+28.39% | 571B | |
-3.55% | 364B | |
+18.16% | 326B | |
+4.36% | 286B | |
+14.72% | 236B | |
+4.77% | 198B | |
-11.04% | 194B | |
-3.69% | 149B |
- Stock Market
- Equities
- NYR Stock
- Company Nyrada Inc.